Inhibition of human DNA topoisomerase IB by nonmutagenic ruthenium(ii)-based compounds with antitumoral activity.

Simple item page
dc.contributor.authorCamargo, Mariana Santoro de
dc.contributor.authorSilva, Monize Martins da
dc.contributor.authorCorrea, Rodrigo de Souza
dc.contributor.authorVieira, Sara Dourado
dc.contributor.authorCastelli, Silvia
dc.contributor.authorD’Anessa, Ilda
dc.contributor.authorGrandis, Rone De
dc.contributor.authorVaranda, Eliana Aparecida
dc.contributor.authorDeflon, Victor Marcelo
dc.contributor.authorDesideri, Alessandro
dc.contributor.authorBatista, Alzir Azevedo
dc.date.accessioned2017-08-10T18:19:06Z
dc.date.available2017-08-10T18:19:06Z
dc.date.issued2016
dc.description.abstractHerein we synthesized two new ruthenium(II) compounds [Ru(pySH)(bipy)(dppb)]PF6 (1) and [Ru(HSpym)(bipy)- (dppb)]PF6 (2) that are analogs to an antitumor agent recently described, [Ru(SpymMe2)(bipy)(dppb)]PF6 (3), where [(Spy) = 2-mercaptopyridine anion; (Spym) = 2-mercaptopyrimidine anion and (SpymMe2) = 4,6-dimethyl-2-mercaptopyrimidine anion]. In vitro cell culture experiments revealed significant antiproliferative activity for 1–3 against HepG2 and MDA-MB-231 tumor cells, higher than the standard anticancer drugs doxorubicin and cisplatin. No mutagenicity is detected when compounds are evaluated by cytokinesis-blocked micronucleus cytome and Ames test in the presence and absence of S9 metabolic activation from rat liver. Interaction studies show that compounds 1–3 can bind to DNA through electrostatic interactions and to albumin through hydrophobic interactions. The three compounds are able to inhibit the DNA supercoiled relaxation mediated by human topoisomerase IB (Top1). Compound 3 is the most efficient Top1 inhibitor and the inhibitory effect is enhanced upon pre-incubation with the enzyme. Analysis of different steps of Top1 catalytic cycle indicates that 3 inhibits the cleavage reaction impeding the binding of the enzyme to DNA and slows down the religation reaction. Molecular docking shows that 3 preferentially binds closer to the residues of the active site when Top1 is free and lies on the DNA groove downstream of the cleavage site in the Top1–DNA complex. Thus, 3 can be considered in further studies for a possible use as an anticancer agent.pt_BR
dc.identifier.citationCAMARGO, M. S. et al. Inhibition of human DNA topoisomerase IB by nonmutagenic ruthenium(ii)-based compounds with antitumoral activity. Metallomics , v. 8, p. 179-192, 2016. Disponível em: <https://pubs.rsc.org/en/content/articlelanding/2016/MT/C5MT00227C#!divAbstract>. Acesso em: 05 ago. 2017.pt_BR
dc.identifier.doihttps://doi.org/10.1039/c5mt00227c
dc.identifier.issn1756-591X
dc.identifier.urihttp://www.repositorio.ufop.br/handle/123456789/8511
dc.identifier.uri2https://pubs.rsc.org/en/content/articlelanding/2016/MT/C5MT00227C#!divAbstractpt_BR
dc.language.isoen_USpt_BR
dc.rightsrestritopt_BR
dc.titleInhibition of human DNA topoisomerase IB by nonmutagenic ruthenium(ii)-based compounds with antitumoral activity.pt_BR
dc.typeArtigo publicado em periodicopt_BR
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ARTIGO_InhibitionHumanDNA.pdf
Size:
2.48 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
924 B
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
DEQUI - Artigos publicados em periódicos